216 related articles for article (PubMed ID: 27025787)
1. Proteomics of thyroid tumours provides new insights into their molecular composition and changes associated with malignancy.
Martínez-Aguilar J; Clifton-Bligh R; Molloy MP
Sci Rep; 2016 Mar; 6():23660. PubMed ID: 27025787
[TBL] [Abstract][Full Text] [Related]
2. Keratin subsets in papillary and follicular thyroid lesions. A paraffin section analysis with diagnostic implications.
Miettinen M; Kovatich AJ; Kärkkäinen P
Virchows Arch; 1997 Dec; 431(6):407-13. PubMed ID: 9428928
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of S100C in thyroid lesions.
Torres-Cabala C; Panizo-Santos A; Krutzsch HC; Barazi H; Namba M; Sakaguchi M; Roberts DD; Merino MJ
Int J Surg Pathol; 2004 Apr; 12(2):107-15. PubMed ID: 15173915
[TBL] [Abstract][Full Text] [Related]
4. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors.
Erickson LA; Jin L; Wollan PC; Thompson GB; van Heerden J; Lloyd RV
Mod Pathol; 1998 Feb; 11(2):169-74. PubMed ID: 9504687
[TBL] [Abstract][Full Text] [Related]
5. S100A9 expression is significantly linked to dedifferentiation of thyroid carcinoma.
Ito Y; Arai K; Ryushi ; Nozawa ; Yoshida H; Tomoda C; Uruno T; Miya A; Kobayashi K; Matsuzuka F; Kuma K; Kakudo K; Miyauchi A
Pathol Res Pract; 2005; 201(8-9):551-6. PubMed ID: 16259107
[TBL] [Abstract][Full Text] [Related]
6. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
Buergy D; Weber T; Maurer GD; Mudduluru G; Medved F; Leupold JH; Brauckhoff M; Post S; Dralle H; Allgayer H
Int J Cancer; 2009 Aug; 125(4):894-901. PubMed ID: 19480010
[TBL] [Abstract][Full Text] [Related]
7. [Problems in pathologic diagnosis of thyroid follicular cell carcinoma].
Li Y; Huo Z; Chen J
Zhonghua Bing Li Xue Za Zhi; 2014 May; 43(5):348-52. PubMed ID: 25030874
[No Abstract] [Full Text] [Related]
8. Expression of cytokeratin 19 in cytologic specimens of thyroid.
Hirokawa M; Inagaki A; Kobayashi H; Kanahara T; Manabe T; Sonoo H
Diagn Cytopathol; 2000 Mar; 22(3):197-8. PubMed ID: 10680002
[No Abstract] [Full Text] [Related]
9. Peroxisome proliferator-activated receptor gamma expression in follicular-patterned thyroid lesions. Caveats for the use of immunohistochemical studies.
Gustafson KS; LiVolsi VA; Furth EE; Pasha TL; Putt ME; Baloch ZW
Am J Clin Pathol; 2003 Aug; 120(2):175-81. PubMed ID: 12931546
[TBL] [Abstract][Full Text] [Related]
10. E-cadherin adhesion molecule and syndecan-1 expression in various thyroid pathologies.
Mitselou A; Ioachim E; Peschos D; Charalabopoulos K; Michael M; Agnantis NJ; Vougiouklakis T
Exp Oncol; 2007 Mar; 29(1):54-60. PubMed ID: 17431390
[TBL] [Abstract][Full Text] [Related]
11. Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma.
Hermann S; Sturm I; Mrozek A; Klosterhalfen B; Hauptmann S; Dörken B; Daniel PT
Int J Cancer; 2001 Jun; 92(6):805-11. PubMed ID: 11351299
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical study of type-1 blood antigen expressions in thyroid tumors: the significance for papillary carcinomas.
Kamoshida S; Ogane N; Yasuda M; Muramatsu T; Bessho T; Kajiwara H; Osamura RY
Mod Pathol; 2000 Jul; 13(7):736-41. PubMed ID: 10912932
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of p27/kip1 expression in thyroid carcinoma.
Resnick MB; Schacter P; Finkelstein Y; Kellner Y; Cohen O
Mod Pathol; 1998 Aug; 11(8):735-9. PubMed ID: 9720501
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of cyclin D1, E2F-1, and Ki-67 in benign and malignant thyroid lesions.
Saiz AD; Olvera M; Rezk S; Florentine BA; McCourty A; Brynes RK
J Pathol; 2002 Oct; 198(2):157-62. PubMed ID: 12237874
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of human tumor-associated antigen, RCAS1, is significantly linked to dedifferentiation of thyroid carcinoma.
Ito Y; Yoshida H; Nakano K; Kobayashi K; Yokozawa T; Hirai K; Matsuzuka F; Matsuura N; Kuma K; Miyauchi A
Oncology; 2003; 64(1):83-9. PubMed ID: 12457035
[TBL] [Abstract][Full Text] [Related]
16. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
[TBL] [Abstract][Full Text] [Related]
17. Changes in integrin and E-cadherin expression in neoplastic versus normal thyroid tissue.
Serini G; Trusolino L; Saggiorato E; Cremona O; De Rossi M; Angeli A; Orlandi F; Marchisio PC
J Natl Cancer Inst; 1996 Apr; 88(7):442-9. PubMed ID: 8618236
[TBL] [Abstract][Full Text] [Related]
18. Analysis of DNA mismatch repair gene expression and mutations in thyroid tumours.
Ruschenburg I; Vollheim B; Stachura J; Cordon-Cardo C; Korabiowska M
Anticancer Res; 2006; 26(3A):2107-12. PubMed ID: 16827152
[TBL] [Abstract][Full Text] [Related]
19. Comparison of metallothionein (MT) and Ki-67 antigen expression in benign and malignant thyroid tumours.
Królicka A; Kobierzycki C; Puła B; Podhorska-Okołów M; Piotrowska A; Rzeszutko M; Rzeszutko W; Rabczyński J; Domosławski P; Wojtczak B; Dawiskiba J; Dzięgiel P
Anticancer Res; 2010 Dec; 30(12):4945-9. PubMed ID: 21187474
[TBL] [Abstract][Full Text] [Related]
20. Expression of the sonic hedgehog pathway molecules in synchronous follicular adenoma and papillary carcinoma of the thyroid gland in predicting malignancy.
Nelson KK; Gattuso P; Xu X; Prinz RA
Surgery; 2010 Oct; 148(4):654-60; discussion 660. PubMed ID: 20797751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
